Contrasting Envoy Medical (NASDAQ:COCH) and Inogen (NASDAQ:INGN)

Inogen (NASDAQ:INGN) and Envoy Medical (NASDAQ:COCH) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, earnings, analyst recommendations, profitability and risk.

Risk & Volatility

Inogen has a beta of 1.06, meaning that its share price is 6% more volatile than the S&P 500. Comparatively, Envoy Medical has a beta of 2.68, meaning that its share price is 168% more volatile than the S&P 500.

Institutional & Insider Ownership

89.9% of Inogen shares are held by institutional investors. Comparatively, 8.6% of Envoy Medical shares are held by institutional investors. 0.6% of Inogen shares are held by company insiders. Comparatively, 0.7% of Envoy Medical shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Inogen and Envoy Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Inogen	-32.46%	-38.98%	-27.03%
Envoy Medical	N/A	N/A	-100.39%

Valuation and Earnings

This table compares Inogen and Envoy Medical’s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inogen	$315.66 million	0.50	-$102.45 million	($4.41)	-1.53
Envoy Medical	$320,000.00	309.93	-$29.91 million	N/A	N/A

Envoy Medical has lower revenue, but higher earnings than Inogen.

Analyst Recommendations

This is a summary of recent ratings for Inogen and Envoy Medical, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inogen	1	2	1	0	2.00
Envoy Medical	0	0	2	0	3.00

Inogen currently has a consensus target price of $7.50, indicating a potential upside of 11.11%. Envoy Medical has a consensus target price of $6.00, indicating a potential upside of 18.58%. Given Envoy Medical’s stronger consensus rating and higher possible upside, analysts clearly believe Envoy Medical is more favorable than Inogen.

Summary

Envoy Medical beats Inogen on 9 of the 12 factors compared between the two stocks.

About Inogen

Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; Simeox airway clearance; batteries; and related accessories. It also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Goleta, California.

About Envoy Medical

Envoy Medical, Inc., a hearing health company, provides medical technologies for the hearing loss spectrum. Its products include personal sound amplification devices; hearing aids; Esteem fully implanted active middle ear implants; auditory osseointegrated implants; and Acclaim cochlear implants. The company was formerly known as Envoy Medical Corporation and changed its name to Envoy Medical, Inc. in September 2023. Envoy Medical, Inc. was founded in 1995 and is headquartered in White Bear Lake, Minnesota.